Former Emergent BioSolutions CEO sued for insider trading

Taking stock of the drug industry, from the lab to the medicine chest

January 15, 2026 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Stefani Reynolds-Pool/Getty Images STAT+ | Former Emergent BioSolutions CEO sued for insider trading, company reaches $900K settlement in N.Y. The New York attorney general says Kramer sold millions in stock after becoming aware of contamination issues in connection with a Covid-era contract. By Ed Silverman STAT+ | Pharmacy compounder files antitrust lawsuit against Eli Lilly and Novo Nordisk The lawsuit comes as the obesity drug market has taken on the aura of a modern-day gold rush with sales forecast to each $95 billion by 2030 By Ed Silverman STAT+ | Regeneron's chief scientist on Trump's drug pricing policy, gene therapy, and the problem with AI At the JP Morgan Healthcare Conference, the longtime biotech executive was, as usual, outspoken in an interview with STAT. By Matthew Herper BioInnovation STAT+ | Novo Nordisk Foundation gives $850M to nonprofit to help commercialize research in Europe  The BioInnovation Institute, which the foundation spun off as a nonprofit five years ago, aims to cultivate stronger culture of company creation. By Andrew Joseph STAT+ | Opinion: After FDA's pivot on clinical AI, we need AI safety research more than ever Recent developments from the FDA, OpenAI, and Doctronic have rapidly made theoretical safety concerns real. By Katherine E. Goodman and Daniel Morgan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser